Current Report Filing (8-k)
October 21 2016 - 3:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
October 20, 2016
ABEONA THERAPEUTICS INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
0-9314
|
83-0221517
|
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification
No.)
|
3333 Lee Parkway, Suite 600
Dallas, TX 75219
(Address of principal executive offices)
(Zip Code)
(214) 214-665-9495
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General
Instruction A.2. below):
¨
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
On October 20, 2016, Abeona Therapeutics
Inc. issued a press release entitled “Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial
at Orphan Drugs & Rare Disease Conference, London UK”. The full text of the press release is furnished as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01
Financial Statements
and
Exhibits.
(d) Exhibits.
Exhibit
No.
|
|
Description
|
99.1
|
|
Press release dated October 20, 2016, entitled “Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at Orphan Drugs & Rare Disease Conference, London UK”
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Abeona Therapeutics Inc.
|
|
(Registrant)
|
|
|
|
|
By:
|
/s/ Stephen B. Thompson
|
|
|
Stephen B. Thompson
|
|
|
Vice President Finance
|
|
|
Chief Accounting Officer
|
Dated: October 21, 2016
EXHIBIT INDEX
Exhibit Number
99.1
|
|
Press release dated October 20, 2016, entitled “Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at Orphan Drugs & Rare Disease Conference, London UK”
|
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2024 to May 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From May 2023 to May 2024